Dipeptidyl peptidase-4 inhibitors and angioedema: A class effect?

Diabetic Medicine

Volumn 30, Issue 4, 2013, Pages e149-e150

  Saisho, Yoshifumi ^a   Itoh, H ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; EZETIMIBE; GLUCOSE; HEMOGLOBIN A1C; LANSOPRAZOLE; VILDAGLIPTIN; ADAMANTANE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG DERIVATIVE; NITRILE; PIPERIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; URACIL;

AGED; ANGIONEUROTIC EDEMA; ARTICLE; CASE REPORT; CLINICAL ARTICLE; DIET THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTROESOPHAGEAL REFLUX; GENERAL CONDITION DETERIORATION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIP DISEASE; LOWER LIP; MALE; MOUTH EDEMA; NON INSULIN DEPENDENT DIABETES MELLITUS; CHEMICALLY INDUCED DISORDER;

ADAMANTANE; AGED; ANGIOEDEMA; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG SUBSTITUTION; HUMANS; MALE; NITRILES; PIPERIDINES; PYRROLIDINES; URACIL;

EID: 84883501384     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12134     Document Type: Article

References (5)

1. Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 2011; 34: S276–278.
2. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 2009; 54: 516–523.
3. Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10 246 patients with type 2 diabetes. BMC Endocr Disord 2010; 10: 7.
4. Ahren B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13: 775–783.
5. Gibbs JP, Fredrickson J, Barbee T, Correa I, Smith B, Lin SL et al. Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. J Clin Pharmacol 2012; 52: 1494–1505.